Novo Nordisk's GLP-1 Weight Loss Drug Achieves Another Breakthrough, High Dividend + AI Pharma Dual Drive, Dividend Healthcare Leader Faces Valuation Reshaping
GLP-1 Track Ripples Again: Novo Nordisk's Oral Weight Loss Drug Clinical SuccessOn the first trading day in August 2026, global pharmaceutical giant Novo Nordisk dropped a bombshell on the...